Novo Nordisk, Minnesota Settle to Resolve Insulin Price Case

 

• Company joins Eli Lilly, Sanofi in capping prices in state
• Multidistrict litigation over insulin costs remains ongoing

Novo Nordisk A/S on Monday became the final insulin manufacturer to reach a proposed settlement agreement with Minnesota, tentatively ending a seven-year lawsuit over the affordability of the diabetes medication.\

https://news.bloomberglaw.com/health-law-and-business/novo-nordisk-minnesota-settle-to-resolve-insulin-pricing-case